The two-year results from the study were published in the New England Journal of Medicine and showed that sparsentan delivered clinically meaningful benefit at 108 weeks with significant ...

The two-year results from the study were published in the New England Journal of Medicine and showed that sparsentan delivered clinically meaningful benefit at 108 weeks with significant proteinuria ...

seeking priority review for traditional approval of FILSPARI ® (sparsentan) for the treatment of focal segmental glomerulosclerosis (FSGS). The submission is supported by results from the Phase 3 ...

Travere Therapeutics and partner CSL Vifor could be weeks away from EU approval of sparsentan for IgA nephropathy, after getting a positive opinion on the drug from the EMA’s human medicines ...

Natalizumab (originator and biosimilar) for treating highly active relapsing–remitting multiple sclerosis after disease-modifying therapy [ID6369] Draft guidance Technology appraisal guidance 2 April ...

and last year it was joined by Travere Therapeutics' Filspari (sparsentan), which is in the same class as atrasentan. Previously, the standard treatment was broad-spectrum immunosuppressant drugs ...

Noonan syndrome or idiopathic short height [ID6536] Technology appraisal guidance Sotagliflozin for treating type 2 diabetes [ID1657] Technology appraisal guidance Sparsentan for treating focal ...

After hours: March 24 at 7:14:10 PM EDT Loading Chart for TVTX ...